{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-154927","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2026-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.926498+00:00","generated_at":"2026-05-15T06:24:43.003638+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aligos: Phase 2 HBV interim – DSMB ups HBeAg- sample size to 100; FDA Fast Track granted","bullets":["DSMB recommended increasing HBeAg- cohort from 74 to 100 participants to optimize power; futility criteria not met.","Study drugs well-tolerated; no viral breakthrough; safety data reviewed across all 174 enrolled participants.","FDA granted Fast Track Designation for pevifoscorvir sodium based on 96-week Phase 1 data.","Topline data from B-SUPREME study remains on track for 2027; enrollment in HBeAg- cohort expected by H2 2026.","Aligos remains blinded to participant-level data; 103 enrolled in HBeAg+ cohort (Part 1a)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-154927","json":"https://secwatch.observer/filing/0001193125-26-154927.json","markdown":"https://secwatch.observer/filing/0001193125-26-154927.md","text":"https://secwatch.observer/filing/0001193125-26-154927.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000119312526154927/0001193125-26-154927-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000119312526154927/d107028d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:24:43.003638+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}